Trial Profile

A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Loperamide; Tamoxifen
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms nextMONARCH 1
Sponsors Eli Lilly and Company

Most Recent Events

09 Jan 2025 Planned End Date changed from 30 Dec 2024 to 1 Dec 2025.
27 Oct 2023 Results deriving baseline and end-of-treatment plasma samples from patients in MONARCH 3 and nextMONARCH (monotherapy arms) to identify somatic genomic alterations, lished in the Clinical Cancer Research
11 Sep 2023 Planned End Date changed from 20 Sep 2023 to 30 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com